Table 2.
Summary of treatment comparisons
| GLS mean ratio (90% CI) | ||
|---|---|---|
| Plasma S/GSK1349572 PK parameter | ATV/RTV + S/GSK1349572 vs. S/GSK1349572 (n = 12) | ATV + S/GSK1349572 vs. S/GSK1349572 (n = 12) |
| AUC(0,τ) | 1.62 | 1.91 |
| (1.50, 1.74) | (1.80, 2.03) | |
| Cmax | 1.34 | 1.50 |
| (1.25, 1.42) | (1.40, 1.59) | |
| Cτ | 2.21 | 2.80 |
| (1.97, 2.47) | (2.52, 3.11) | |
| CL/F | 0.618 | 0.523 |
| (0.574, 0.667) | (0.494, 0.555) | |
| t1/2 | 1.81 | 1.90 |
| (1.64, 1.99) | (1.68, 2.14) | |
ATV, atazanavir; AUC(0,τ), area under the concentration–time curve during a dosing interval; CI, confidence interval; CL/F, apparent oral clearance; Cmax, observed maximal concentration; Cτ, concentration at end of dosing interval at steady state; GLS, geometric least squares; PK, pharmacokinetic; RTV, ritonavir; t1/2, elimination half-life.